Abstract:Background: Recombinant vaccinia virus (rVV) strains expressing the immunomodulatory cholera toxin B subunit (CTB) fused to the autoantigen glutamic acid decarboxylase (GAD) or the immunosuppressive cytokine interleukin-10 (IL-10) were independently able to generate only low levels of immune suppression of type 1 diabetes mellitus (T1DM). Here we suggest that a vaccinia virus (VV)-mediated combination of CTB::GAD fusion and IL-10 proteins promises a effective and durable immunotherapeutic strategy for T1DM. Methods: To explore this hypothesis, a CTB::GAD fusion gene was co-delivered with a gene encoding IL-10 by rVV infection (rVV-CTB::GAD + rVV-IL10) into 5-7-week-old non-obese diabetic (NOD) mice. The mice were assessed for vaccine protection against development of hyperglycemia from 12 to 64 weeks of age by assessment of pancreatic inflammation (insulitis) and splenocyte-secreted interferon-gamma and IL-10 cytokine levels. Results: By 36 weeks of age, from 54% to 80% of the mice in the negative control animal groups (either mock-infected or inoculated with unrelated plasmid or VV) had developed hyperglycemia. Similarly, no statistically significant improvement in protection against diabetes onset was achieved by inoculation with VV expressing CTB::GAD or IL-10 independently. Surprisingly, only 20% of mice co-inoculated with rVV-CTB::GAD + rVV-IL10 developed hyperglycemia by 28 weeks of age. Other treatment groups developed hyperglycemia by 32-36 weeks. After 36 weeks, diabetes incidence no longer increased in any groups until the end of experiment at 64 weeks of age. Histological analysis of pancreatic tissues of hyperglycemic mice revealed high levels of intra-islet insulitis. Analysis of insulitis at termination of the experiment showed that euglycemic mice co-inoculated with VV expressing CTB::GAD and IL-10 had more effectively reduced inflammation in comparison with the other groups. Conclusions: A combinatorial vaccination strategy based on VV co-delivery of genes encoding the immunoenhanced autoantigen CTB::GAD and the anti-inflammatory cytokine IL-10 can maintain effective and durable euglycemia and immunological homeostasis in NOD mice with prediabetes.

Suppression of diabetes in non-obese diabetic (NOD) mice by oral administration of a cholera toxin B subunit-insulin B chain fusion protein vaccine produced in silkworm

Oral administration of a cholera toxin B subunit-insulin fusion protein produced in silkworm protects against autoimmune diabetes

Protection against autoimmune diabetes by silkworm-produced GFP-tagged CTB-insulin fusion protein

Oral administration of CTB insulin B chain produced in silkworm delays the diabetes development in NOD mice

Oral Delivery of Single-Chain Insulin (SCI-59) Analog by Bacterium-Like Particles (blps) Induces Oral Tolerance and Prevents Autoimmune Diabetes in NOD Mice.

Expression of Cholera Toxin B Subunit and Assembly As Functional Oligomers in Silkworm

Oral Delivery of the Intracellular Domain of the Insulinoma-Associated Protein 2 (Ia-2Ic) by Bacterium-Like Particles (blps) Prevents Type 1 Diabetes Mellitus in NOD Mice

Oral Delivery of Bi-Autoantigens by Bacterium-Like Particles (blps) Against Autoimmune Diabetes in NOD Mice.

Oral Administration of Silkworm-Produced GAD65 and Insulin Bi-Autoantigens against Type 1 Diabetes

A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes

Intramuscular Injection of Interleukin-10 Plasmid DNA Prevented Autoimmune Diabetes in Mice

A Shark Liver Gene-Derived Active Peptide Expressed in the Silkworm, Bombyx Mori: Preliminary Studies for Oral Administration of the Recombinant Protein.

Oral Administration of a Fusion Protein Between the Cholera Toxin B Subunit and the 42-Amino Acid Isoform of Amyloid-Β Peptide Produced in Silkworm Pupae Protects Against Alzheimer's Disease in Mice.

Persistent suppression of type 1 diabetes by a multicomponent vaccine containing a cholera toxin B subunit-autoantigen fusion protein and complete Freund's adjuvant

Protective Response Against Type 1 Diabetes in Nonobese Diabetic Mice after Coimmunization with Insulin and Dna Encoding Proinsulin

Anti-Diabetic Effects of CTB-APSL Fusion Protein in Type 2 Diabetic Mice

Autoantigens plus interleukin-10 suppress diabetes autoimmunity

Active Tolerance Induction and Prevention of Autoimmune Diabetes by Immunogene Therapy Using Recombinant Adenoassociated Virus Expressing Glutamic Acid Decarboxylase 65 Peptide Gad(500-585)

Immunotherapy of Autoimmune Diabetes by Nasal Administration of Tandem Glutamic Acid Decarboxylase 65 Peptides

Mechanism of Action of Oral Salmonella-Based Vaccine to Prevent and Reverse Type 1 Diabetes in NOD Mice

Effect of cholera toxoid-proinsulin conjugate and cholera toxin B subunit admixtures on spontaneous autoimmune diabetes